Estimating Subject-Specific Treatment Differences for Risk-Benefit Assessment with Applications to Beta-Blocker Effectiveness Trials

Springer Proceedings in Mathematics and Statistics

Volumn 55, Issue , 2013, Pages 75-86

  Claggett, Brian ^a   Tian, Lu ^b   Zhao, Lihui ^c   Castagno, Davide ^d   Wei, Lee Jen ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC HEART FAILURES; CLINICAL PRACTICES; CLINICAL TRIAL; CONFIDENCE INTERVAL; INTERIM ANALYSIS; NON-PARAMETRIC ESTIMATES; SUBJECT-SPECIFIC; TREATMENT EFFECTS;

ESTIMATION; MEDICAL APPLICATIONS; RISK ASSESSMENT; RISK PERCEPTION; STATISTICAL METHODS; UNCERTAINTY ANALYSIS;

PATIENT TREATMENT;

EID: 84886050009     PISSN: 21941009     EISSN: 21941017     Source Type: Conference Proceeding    
DOI: 10.1007/978-1-4614-7846-1_7     Document Type: Conference Paper

References (15)

1. Beta-Blocker Evaluation of Survival Trial Investigators (2001). A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. New England Journal of Medicine 344, 1659-1667.
2. Bickel, P. and Rosenblatt, M. (1973). On some global measures of the deviations of density function estimates. The Annals of Statistics pages 1071-1095.
3. Cai, T., Tian, L., Uno, H., Solomon, S., andWei, L. (2010). Calibrating parametric subject-specific risk estimation. Biometrika 97, 389-404.
4. Cai, T., Tian, L., Wong, P., and Wei, L. (2011). Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics 12, 270-282.
5. Castagno, D., Jhund, P. S., McMurray, J. J., Lewsey, J. D., Erdmann, E., Zannad, F., & Dargie, H. J. et al. (2010). Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. European journal of heart failure, 12(6), 607-616.
6. Domanski, M., Krause-Steinrauf, H., Massie, B., Deedwania, P., Follmann, D., Kovar, D., Murray, D., Oren, R., Rosenberg, Y., Young, J., et al. (2003). A comparative analysis of the results from 4 trials of [beta]-blocker therapy for heart failure: Best, cibis-ii, merit-hf, and copernicus. Journal of cardiac failure 9, 354-363.
7. Kent, D. and Hayward, R. (2007). Limitations of applying summary results of clinical trials to individual patients. JAMA: the journal of the American Medical Association 298, 1209-1212.
8. Li, Y., Tian, L., and Wei, L. (2011). Estimating subject-specific dependent competing risk profile with censored event time observations. Biometrics 67, 427-435.
9. Lin, D., Wei, L., and Ying, Z. (1993). Checking the cox model with cumulative sums of martingalebased residuals. Biometrika 80, 557-572.
10. Mammen, E. (1993). Bootstrap and wild bootstrap for high dimensional linear models. The Annals of Statistics 21, 255-285.
11. Park, Y. and Wei, L. (2003). Estimating subject-specific survival functions under the accelerated failure time model. Biometrika 90, 717-723.
12. Uno, H., Cai, T., Tian, L., and Wei, L. J. (2007). Evaluating prediction rules for t-year survivors with censored regression models. Journal of the American Statistical Association 102, 527-537.
13. Wang, R., Lagakos, S., Ware, J., Hunter, D., and Drazen, J. (2007). Statistics in medicine- reporting of subgroup analyses in clinical trials. New England Journal of Medicine 357, 2189-2194.
14. Wu, C. (1986). Jackknife, bootstrap and other resampling methods in regression analysis. The Annals of Statistics 14, 1261-1295.
15. Zheng, Y., Cai, T., and Feng, Z. (2006). Application of the time-dependent roc curves for prognostic accuracy with multiple biomarkers. Biometrics 62, 279-287.